Gilead Sciences, Inc. $GILD Shares Bought by National Pension Service

National Pension Service raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,062,393 shares of the biopharmaceutical company’s stock after purchasing an additional 40,925 shares during the quarter. National Pension Service’s holdings in Gilead Sciences were worth $386,903,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. California State Teachers Retirement System lifted its holdings in shares of Gilead Sciences by 12,498.3% during the second quarter. California State Teachers Retirement System now owns 241,168,657 shares of the biopharmaceutical company’s stock worth $30,469,248,000 after purchasing an additional 239,254,365 shares during the period. BlackRock Inc. acquired a new position in Gilead Sciences in the 2nd quarter valued at $15,393,785,000. Norges Bank purchased a new position in Gilead Sciences during the 4th quarter worth $2,617,152,000. Legal & General Group Plc acquired a new stake in shares of Gilead Sciences in the 2nd quarter worth $1,316,606,000. Finally, Deutsche Bank AG purchased a new stake in shares of Gilead Sciences in the second quarter valued at about $918,387,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel O’Day sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $148.64, for a total transaction of $2,229,600.00. Following the completion of the transaction, the chief executive officer directly owned 577,133 shares in the company, valued at approximately $85,785,049.12. This trade represents a 2.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the transaction, the director owned 10,066 shares of the company’s stock, valued at approximately $1,459,771.32. The trade was a 33.19% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 105,000 shares of company stock worth $14,495,820 in the last 90 days. Insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Down 0.7%

GILD opened at $145.65 on Thursday. The business’s fifty day moving average is $137.96 and its two-hundred day moving average is $136.28. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The company has a market cap of $180.60 billion, a price-to-earnings ratio of -54.55 and a beta of 0.33. Gilead Sciences, Inc. has a one year low of $108.46 and a one year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. During the same quarter in the prior year, the company earned $2.01 earnings per share. Gilead Sciences’s revenue was up 10.6% compared to the same quarter last year. Analysts anticipate that Gilead Sciences, Inc. will post -0.48 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is presently -122.85%.

Analysts Set New Price Targets

Several research analysts recently issued reports on GILD shares. Morgan Stanley cut their price target on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a report on Monday, July 27th. Wall Street Zen lowered Gilead Sciences from a “buy” rating to a “hold” rating in a report on Saturday, September 5th. HSBC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the stock from $133.00 to $155.00 in a research report on Monday, July 6th. Royal Bank Of Canada increased their target price on Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research note on Wednesday, August 5th. Finally, Barclays reduced their price target on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $158.04.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company’s research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.

Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.